Antiviral treatment guidelines for middle east respiratory syndrome

Rapid Response Team

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Middle East respiratory syndrome (MERS) is an acute infectious disease of the respiratory system caused by the new betacoronavirus (MERS coronavirus, MERS-CoV), which shows high mortality rates. The typical symptoms of MERS are fever, cough, and shortness of breath, and it is often accompanied by pneumonia. The MERS-CoV was introduced to Republic of Korea in May 2015 by a patient returning from Saudi Arabia. The disease spread mostly through hospital infections, and by the time the epidemic ended in August, the total number of confirmed diagnoses was 186, among which 36 patients died. Reflecting the latest evidence for antiviral drugs in the treatment of MERS-CoV infection and the experiences of treating MERS patients in Republic of Korea, these guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.

Original languageEnglish
Pages (from-to)212-222
Number of pages11
JournalInfection and Chemotherapy
Volume47
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Coronavirus Infections
Antiviral Agents
Guidelines
Republic of Korea
Therapeutics
Saudi Arabia
Acute Disease
Cross Infection
Infection
Cough
Respiratory System
Dyspnea
Communicable Diseases
Pneumonia
Fever
Mortality

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Rapid Response Team. / Antiviral treatment guidelines for middle east respiratory syndrome. In: Infection and Chemotherapy. 2015 ; Vol. 47, No. 3. pp. 212-222.
@article{8586e5f9d2cd406aaaba67dec1f298d5,
title = "Antiviral treatment guidelines for middle east respiratory syndrome",
abstract = "Middle East respiratory syndrome (MERS) is an acute infectious disease of the respiratory system caused by the new betacoronavirus (MERS coronavirus, MERS-CoV), which shows high mortality rates. The typical symptoms of MERS are fever, cough, and shortness of breath, and it is often accompanied by pneumonia. The MERS-CoV was introduced to Republic of Korea in May 2015 by a patient returning from Saudi Arabia. The disease spread mostly through hospital infections, and by the time the epidemic ended in August, the total number of confirmed diagnoses was 186, among which 36 patients died. Reflecting the latest evidence for antiviral drugs in the treatment of MERS-CoV infection and the experiences of treating MERS patients in Republic of Korea, these guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.",
author = "{Rapid Response Team} and Chong, {Yong Pil} and Song, {Joon Young} and Seo, {Yu Bin} and Choi, {Jae Phil} and Shin, {Hyoung Shik} and Yoon, {Hee Jung} and JunYong Choi and Kim, {Tae Hyong} and Choi, {Young Hwa} and Kim, {Hong Bin} and Yoon, {Ji Hyun} and Jacob Lee and Eom, {Joong Sik} and Song, {Joon Young} and Lee, {Sang Oh} and Oh, {Won Sup} and Cheong, {Hee Jin} and Song, {Young Goo} and Choi, {Jung Hyun} and Kim, {Woo Joo}",
year = "2015",
month = "1",
day = "1",
doi = "10.3947/ic.2015.47.3.212",
language = "English",
volume = "47",
pages = "212--222",
journal = "Infection and Chemotherapy",
issn = "2093-2340",
publisher = "Taehan Kamyom Hakhoe, Taehan Hwahak Yopop Hakhoe",
number = "3",

}

Antiviral treatment guidelines for middle east respiratory syndrome. / Rapid Response Team.

In: Infection and Chemotherapy, Vol. 47, No. 3, 01.01.2015, p. 212-222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiviral treatment guidelines for middle east respiratory syndrome

AU - Rapid Response Team

AU - Chong, Yong Pil

AU - Song, Joon Young

AU - Seo, Yu Bin

AU - Choi, Jae Phil

AU - Shin, Hyoung Shik

AU - Yoon, Hee Jung

AU - Choi, JunYong

AU - Kim, Tae Hyong

AU - Choi, Young Hwa

AU - Kim, Hong Bin

AU - Yoon, Ji Hyun

AU - Lee, Jacob

AU - Eom, Joong Sik

AU - Song, Joon Young

AU - Lee, Sang Oh

AU - Oh, Won Sup

AU - Cheong, Hee Jin

AU - Song, Young Goo

AU - Choi, Jung Hyun

AU - Kim, Woo Joo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Middle East respiratory syndrome (MERS) is an acute infectious disease of the respiratory system caused by the new betacoronavirus (MERS coronavirus, MERS-CoV), which shows high mortality rates. The typical symptoms of MERS are fever, cough, and shortness of breath, and it is often accompanied by pneumonia. The MERS-CoV was introduced to Republic of Korea in May 2015 by a patient returning from Saudi Arabia. The disease spread mostly through hospital infections, and by the time the epidemic ended in August, the total number of confirmed diagnoses was 186, among which 36 patients died. Reflecting the latest evidence for antiviral drugs in the treatment of MERS-CoV infection and the experiences of treating MERS patients in Republic of Korea, these guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.

AB - Middle East respiratory syndrome (MERS) is an acute infectious disease of the respiratory system caused by the new betacoronavirus (MERS coronavirus, MERS-CoV), which shows high mortality rates. The typical symptoms of MERS are fever, cough, and shortness of breath, and it is often accompanied by pneumonia. The MERS-CoV was introduced to Republic of Korea in May 2015 by a patient returning from Saudi Arabia. The disease spread mostly through hospital infections, and by the time the epidemic ended in August, the total number of confirmed diagnoses was 186, among which 36 patients died. Reflecting the latest evidence for antiviral drugs in the treatment of MERS-CoV infection and the experiences of treating MERS patients in Republic of Korea, these guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.

UR - http://www.scopus.com/inward/record.url?scp=84945570358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945570358&partnerID=8YFLogxK

U2 - 10.3947/ic.2015.47.3.212

DO - 10.3947/ic.2015.47.3.212

M3 - Article

VL - 47

SP - 212

EP - 222

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

SN - 2093-2340

IS - 3

ER -